Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of
muscle invasive UTUC patients in several studies. This study is designed to investigate the
safety and efficacy of neoadjuvant PD-1 monoclonal antibody in patients with locally advanced
upper urinary tract urothelial carcinoma (UTUC) which are ineligible for cisplatin.
Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered
to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a
mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The safety,
tolerability, and efficacy of tislelizumab in patients with PD-L1 positive urothelial
carcinoma who progressed during/following platinum-containing therapy was proved in a phase 2
trial (CTR20170071). This trial focuses on the efficacy of Tislelizumab to induce
pathological down-staging of locally advanced UTUC in neoadjuvant setting.